Clinical trial
Prospective Single-centre Randomized Observer-blind Placebo-controlled Parallel-group Phase IIa Clinical Trial to Investigate the Safety and Efficacy of Ripasudil 0.4% Eye Drops After Descemetorhexis in Patients With Moderate to Advanced Fuchs Endothelial Corneal Dystrophy (FECD)
NCT03575130 is registered in ClinicalTrials.gov with University of Erlangen-Nürnberg Medical School as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Prospective Single-centre Randomized Observer-blind Placebo-controlled Parallel-group Phase IIa Clinical Trial to Investigate the Safety and Efficacy of Ripasudil 0.4% Eye Drops After Descemetorhexis in Patients With Moderate to Advanced Fuchs Endothelial Corneal Dystrophy (FECD)
- Lead sponsor
- University of Erlangen-Nürnberg Medical School
- Phase
- Phase 2
- Overall status
- Unknown status
- Start date
- June 5, 2018
- Completion date
- December 31, 2018
- Enrollment
- 21 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
cornea guttata, corneal endothelial cell loss, corneal endothelial dystrophy, fuchs dystrophy, fuchs' endothelial dystrophy